Bicara Therapeutics appoints Jeremy Bender and Christy Oliger to board; Kiran Mazumdar-Shaw retires

Bicara Therapeutics Inc.

Kiran Mazumdar-Shaw resigned from board effective July 28, 2026; no disagreement with company.
Jeremy Bender (former CEO, Day One Biopharmaceuticals) and Christy Oliger (former SVP, Genentech) appointed to board effective July 28, 2026.
Board size increased from nine to ten directors; Bender and Oliger each receive initial option award of 38,950 shares.
New Launch Readiness Committee formed with Kate Haviland as chair, Bender and Oliger as members.
Appointments support Bicara's transition to commercial-stage focus on ficerafusp alfa.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.